WO2011163594A3 - Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives - Google Patents

Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives Download PDF

Info

Publication number
WO2011163594A3
WO2011163594A3 PCT/US2011/041830 US2011041830W WO2011163594A3 WO 2011163594 A3 WO2011163594 A3 WO 2011163594A3 US 2011041830 W US2011041830 W US 2011041830W WO 2011163594 A3 WO2011163594 A3 WO 2011163594A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamate
prodrug
prodrugs
carbonate
ester
Prior art date
Application number
PCT/US2011/041830
Other languages
French (fr)
Other versions
WO2011163594A2 (en
Inventor
Laura Cook Blumberg
Julius F. Remenar
Orn Almarrson
Tarek A. Zeidan
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Priority to JP2013516803A priority Critical patent/JP5848761B2/en
Priority to ES11798995.4T priority patent/ES2691671T3/en
Priority to NZ604423A priority patent/NZ604423A/en
Priority to AU2011270701A priority patent/AU2011270701B2/en
Priority to EP11798995.4A priority patent/EP2585066B1/en
Priority to CA2802733A priority patent/CA2802733C/en
Publication of WO2011163594A2 publication Critical patent/WO2011163594A2/en
Publication of WO2011163594A3 publication Critical patent/WO2011163594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Abstract

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
PCT/US2011/041830 2010-06-24 2011-06-24 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives WO2011163594A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2013516803A JP5848761B2 (en) 2010-06-24 2011-06-24 Prodrugs of NH acidic compounds: derivatives of esters, carbonates, carbamates and phosphonates
ES11798995.4T ES2691671T3 (en) 2010-06-24 2011-06-24 Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
NZ604423A NZ604423A (en) 2010-06-24 2011-06-24 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011270701A AU2011270701B2 (en) 2010-06-24 2011-06-24 Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
EP11798995.4A EP2585066B1 (en) 2010-06-24 2011-06-24 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2802733A CA2802733C (en) 2010-06-24 2011-06-24 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35834810P 2010-06-24 2010-06-24
US61/358,348 2010-06-24

Publications (2)

Publication Number Publication Date
WO2011163594A2 WO2011163594A2 (en) 2011-12-29
WO2011163594A3 true WO2011163594A3 (en) 2013-08-01

Family

ID=45353112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/041830 WO2011163594A2 (en) 2010-06-24 2011-06-24 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Country Status (8)

Country Link
US (4) US8592427B2 (en)
EP (1) EP2585066B1 (en)
JP (2) JP5848761B2 (en)
AU (1) AU2011270701B2 (en)
CA (1) CA2802733C (en)
ES (1) ES2691671T3 (en)
NZ (1) NZ604423A (en)
WO (1) WO2011163594A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5733841B2 (en) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Heterocyclic compounds for the treatment of neurological and mental disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
US9670200B2 (en) * 2010-01-07 2017-06-06 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
FI3156056T3 (en) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
JO3227B1 (en) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
AU2012351747B2 (en) 2011-12-15 2016-05-12 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
AU2013257715B2 (en) * 2012-05-08 2016-05-05 Cellixbio Private Limited Compositions and methods for suppression of carbonic anhydrase activity
CA2876359C (en) * 2012-06-11 2020-01-21 Bristol-Myers Squibb Company Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino) quinazolin-2-yl] pyridine-3-sulfonamide
CN102863436B (en) * 2012-06-19 2018-02-09 重庆医科大学 Tetrahydrothiazole diketone derivatives and its preparation and use
EP2888234B1 (en) * 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptens of aripiprazole and their use in immunoassays
PT3354751T (en) 2012-08-21 2019-12-17 Janssen Pharmaceutica Nv Antibodies to aripiprazole and use thereof
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
CN108517014A (en) 2012-08-21 2018-09-11 詹森药业有限公司 The antibody and application thereof of Risperidone haptens
US9611332B2 (en) * 2012-08-21 2017-04-04 Janssen Pharmaceutica Nv Antibodies to aripiprazole haptens and use thereof
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
PT2888593T (en) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6654042B2 (en) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition with improved storage stability
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
BR112016010862B1 (en) 2013-11-15 2022-11-29 Chimerix, Inc MORPHIC FORMS OF HEXADECYLOXYPROPYLPHOSPHONATE ESTERS, THEIR METHOD OF PREPARATION AND COMPOSITION INCLUDING SAID morphic FORM
WO2015127316A1 (en) * 2014-02-21 2015-08-27 Micurx Pharmaceuticals, Inc. Water-soluble o-carbonyl phosphoramidate prodrugs for therapeutic administration
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US9969688B2 (en) 2014-10-24 2018-05-15 Hisamitsu Pharmaceutical Co., Inc. Roflumilast prodrugs
WO2016069637A1 (en) * 2014-10-28 2016-05-06 The Regents Of The University Of California Sulfonamides that activate aba receptors
CN112142749A (en) * 2015-02-12 2020-12-29 NeOnc技术股份有限公司 Perilla alcohol derivatives, pharmaceutical compositions and uses thereof
CN107531647A (en) 2015-05-05 2018-01-02 辉瑞大药厂 2 thiopyrimidine ketones
CN104892514A (en) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 Novel imidazole compound
FI3328827T3 (en) 2015-07-31 2023-09-26 Univ Johns Hopkins Prodrugs of glutamine analogs
CA2999766A1 (en) 2015-09-22 2017-03-30 Graybug Vision, Inc. Compounds and compositions for the treatment of ocular disorders
WO2017076213A1 (en) * 2015-11-02 2017-05-11 苏州旺山旺水生物医药有限公司 Benzimidazole compound, preparation method thereof and usage
CN108367079B (en) 2015-11-12 2022-11-22 灰色视觉公司 Aggregated microparticles for therapy
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
ES2954596T3 (en) 2015-12-23 2023-11-23 Univ British Columbia Lipid-bound prodrugs
CN107353303B (en) * 2016-05-09 2020-09-01 上海奥博生物医药技术有限公司 Preparation method of fosaprepitant phosphate intermediate
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
RU2019139817A (en) 2017-05-10 2021-06-10 Грейбуг Вижн, Инк. DELAYED RELEASE MICROPARTICLES AND THEIR SUSPENSIONS FOR DRUG THERAPY
CN107217480B (en) * 2017-06-22 2018-10-02 盐城工学院 Finishing agent with antibacterial and flame retardant property and its preparation method and application method
US11485725B2 (en) 2017-12-15 2022-11-01 Auransa Inc. Derivatives of piperlongumine and uses thereof
CA3091950A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
JP7384812B2 (en) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド Aripiprazole dosing strategy
US11273137B2 (en) 2018-09-04 2022-03-15 Board Of Trustees Of Michigan State University Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene
CN114206463A (en) * 2020-06-30 2022-03-18 苏州艾博生物科技有限公司 Lipid compounds and lipid nanoparticle compositions
CN111909155B (en) * 2020-08-21 2022-10-18 东莞理工学院 Proteolysis targeting chimera, prodrug molecule for improving oral bioavailability of proteolysis targeting chimera and application of prodrug molecule
CN113402547B (en) * 2021-05-27 2023-05-16 兰州大学 Synthesis method of N-acyl phosphoramide compound
WO2023186023A1 (en) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 N-substituted quinolinone compound, preparation method therefor and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694006A (en) * 1983-06-30 1987-09-15 A/S Gea Acyl- or acyloxymethyl-allopurinol prodrugs
US5034401A (en) * 1988-07-12 1991-07-23 Synthelabo Derivatives of (1-hydroxy-2-piperidylalkyl-indol-2-ones, 2-quinolinones, 2-benzo(B)azapinones, benzimidazol-2-ones, and quinazolin-2-ones, their preparation and their application in therapeutics
US20060276412A1 (en) * 2005-05-31 2006-12-07 Gary Tollefson Methods and compositions for managing psychotic disorders
US20070031513A1 (en) * 2003-05-23 2007-02-08 Tetsuro Kikuchi Carbostyril derivatives and mood stabilizers for treating mood disorders
US20070191611A1 (en) * 2004-05-05 2007-08-16 Cipla Limited Synthesis of antidiabetic rosigltazone derivatives
US20090143434A1 (en) * 2007-12-03 2009-06-04 Brown Arthur M Methods of using domperidone to terminate acute episodes of cardiac arrhythmia, to restore normal sinus rhythm or heart rate, to prevent recurrence of cardiac arrhythmia and to maintain normal sinus rhythm or heart rate in mammals

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1594847A1 (en) * 1966-08-09 1971-05-27 Bayer Ag Whitening agents
DE2306374A1 (en) * 1973-02-09 1974-08-15 Bayer Ag 2-Oxo-4-hydroxy tetrahydro quinazoline-4-carboxamides - prepd by reacting isatin-N-carboxamides with amines and useful as (inters for) dyes
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
EP0005828B1 (en) 1978-06-06 1981-03-11 Hoechst Aktiengesellschaft New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
FI77852C (en) 1981-02-17 1989-05-10 Otsuka Pharma Co Ltd Process for the preparation of novel, such as cardiac drugs, useful s unsubstituted amide and (saturated heterocycle) carbonyl carbostyril derivatives.
AU532361B2 (en) 1981-09-01 1983-09-29 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
IT1212743B (en) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa QUATERNARY SALTS OF BENZO DERIVATIVES [1,4] DIAZEPINONICS, PYRID [1,4] BENZODIAZEPINONICS, PRIDO [1,5] BENZODIAZEPINONICS AND THEIR PHARMACOLOGICAL LIFE ACTS
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DK588486A (en) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd USE OF A COMPOUND TO TREAT HYPOXY
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (en) * 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
DK238190D0 (en) * 1990-10-03 1990-10-03 Lundbeck & Co As H DEPOT DERIVATIVES
MX9201991A (en) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited DERIVATIVES OF PIPERAZINE AND PROCEDURE FOR ITS PREPARATION.
TW226016B (en) 1991-12-30 1994-07-01 Sterling Winthrop Inc
GB9204565D0 (en) * 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
WO1993025197A1 (en) 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994000113A2 (en) * 1992-06-27 1994-01-06 Smithkline Beecham Plc Medicaments containing 5-ht4 receptor antagonists
JP3526575B2 (en) 1993-03-08 2004-05-17 エーザイ株式会社 Phosphonic acid derivatives
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
DE4345266C2 (en) 1993-10-04 1996-12-19 Luitpold Pharma Gmbh Heterocyclic carbamates, process for their preparation and pharmaceuticals
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
IT1275903B1 (en) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia ESTERS AND AMIDES OF 1,4-PIPERIDINE DISPLACED
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
ES2226129T3 (en) * 1997-05-30 2005-03-16 Banyu Pharmaceutical Co., Ltd. DERIVATIVES OF 2-0X0IMIDAZOL.
WO1998056422A1 (en) 1997-06-13 1998-12-17 The University Of Kansas Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985856A (en) 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
ATE346841T1 (en) 1998-08-26 2006-12-15 Aventis Pharma Ltd AZABICYCLO COMPOUNDS WHICH MODULATE THE INHIBITION OF CELL ADHESION
FR2783519B1 (en) 1998-09-23 2003-01-24 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU766233B2 (en) * 1999-10-13 2003-10-09 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2005503351A (en) 2001-04-03 2005-02-03 アリックス セラピューティクス Ultra-short acting opioids for transdermal application
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
AR038420A1 (en) 2002-02-15 2005-01-12 Glaxo Group Ltd AMIDA COMPOSITE, PROCEDURE FOR THE PREPARATION OF THE SAME, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
PL372413A1 (en) 2002-03-20 2005-07-25 Bristol-Myers Squibb Company Phosphate prodrugs of fluorooxindoles
DE60327225D1 (en) 2002-08-20 2009-05-28 Bristol Myers Squibb Co ARIPIPRAZOL COMPLEX FORMULATION AND METHOD
MXPA05002734A (en) * 2002-10-24 2005-05-23 Pfizer Prod Inc Acyl derivatives of 5- (2-(4 -(1, 2 benzisothiazole -3- yl)-1- piperazinyl) ethyl)- 6-chloro -1, 3-dihydro -2h -indol-2 -one having neuroleptic activity.
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
DE10303669A1 (en) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. New quaternary ammonioalkyl carbonate esters useful for treating bacterial and fungal infections and potentially useful for regulating cholesterol biosynthesis
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2006523237A (en) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド PI-3 kinase inhibitor prodrug
WO2004100992A2 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CA2551346A1 (en) 2003-12-31 2005-07-21 Warner-Lambert Company Llc N-substituted piperidine and piperazine derivatives
KR20060110006A (en) 2004-02-13 2006-10-23 화이자 프로덕츠 인크. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
JPWO2005115993A1 (en) * 2004-05-31 2008-03-27 萬有製薬株式会社 Quinazoline derivatives
WO2006037090A2 (en) 2004-09-28 2006-04-06 Purdue Research Foundation Drug-phosphate conjugates as prodrugs
EP1813603A1 (en) * 2004-11-17 2007-08-01 Kissei Pharmaceutical Co., Ltd. Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
JP4315393B2 (en) * 2005-04-14 2009-08-19 大塚製薬株式会社 Heterocyclic compounds
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
KR100781704B1 (en) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 Novel pyridine derivatives, process for preparing thereof and pharmaceutical compositions containing them
US7521557B2 (en) * 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070185069A1 (en) 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
JP2009528266A (en) * 2006-01-18 2009-08-06 シェーリング コーポレイション Cannabinoid receptor modifier
US20090325944A1 (en) * 2006-04-12 2009-12-31 Suzanne Walker Kahne Methods and Compositions for Modulating Glycosylation
MX2009002125A (en) * 2006-08-26 2009-03-09 Abbott Gmbh & Co Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use.
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
EP2114897A2 (en) * 2006-09-12 2009-11-11 Pfizer Products Inc. Benzimidazolone derivatives
WO2008034041A2 (en) 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
KR20090086627A (en) 2006-12-05 2009-08-13 노이로제스엑스, 인코포레이티드 Prodrugs and methods of making and using the same
CA2672270A1 (en) 2006-12-15 2008-06-26 Gennadi V. Glinksy Treatments of therapy resistant diseases and drug combinations for treating the same
TWI325694B (en) 2006-12-15 2010-06-01 Ind Tech Res Inst All digital delay locked loop
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
ES2423485T3 (en) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Associations of 5-HT2A inverse agonists and antagonists with antipsychotics
PL2142529T3 (en) 2007-04-27 2014-06-30 Purdue Pharma Lp Trpv1 antagonists and uses thereof
CL2008001563A1 (en) 2007-05-30 2008-10-10 Wyeth6 3 COMPOUNDS DERIVED FROM BENZODIOXANES CONDENSED WITH HETEROCICLES; PREPARATION METHOD; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, PANIC CRISIS, AMONG OTHERS.
WO2009052467A1 (en) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010004390A1 (en) * 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
TWI453207B (en) * 2008-09-08 2014-09-21 Signal Pharm Llc Aminotriazolopyridines, compositions thereof, and methods of treatment therewith
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
JP5733841B2 (en) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Heterocyclic compounds for the treatment of neurological and mental disorders
WO2011084849A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
US20110166194A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Asenapine Prodrugs
US9670200B2 (en) 2010-01-07 2017-06-06 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
US20110166156A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
US9107911B2 (en) 2010-01-07 2015-08-18 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
CN102947269B (en) * 2010-04-19 2015-11-25 新陈代谢解决方案开发公司 The new synthetic method of thiazolidinedione compound
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694006A (en) * 1983-06-30 1987-09-15 A/S Gea Acyl- or acyloxymethyl-allopurinol prodrugs
US5034401A (en) * 1988-07-12 1991-07-23 Synthelabo Derivatives of (1-hydroxy-2-piperidylalkyl-indol-2-ones, 2-quinolinones, 2-benzo(B)azapinones, benzimidazol-2-ones, and quinazolin-2-ones, their preparation and their application in therapeutics
US20070031513A1 (en) * 2003-05-23 2007-02-08 Tetsuro Kikuchi Carbostyril derivatives and mood stabilizers for treating mood disorders
US20070191611A1 (en) * 2004-05-05 2007-08-16 Cipla Limited Synthesis of antidiabetic rosigltazone derivatives
US20060276412A1 (en) * 2005-05-31 2006-12-07 Gary Tollefson Methods and compositions for managing psychotic disorders
US20090143434A1 (en) * 2007-12-03 2009-06-04 Brown Arthur M Methods of using domperidone to terminate acute episodes of cardiac arrhythmia, to restore normal sinus rhythm or heart rate, to prevent recurrence of cardiac arrhythmia and to maintain normal sinus rhythm or heart rate in mammals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2585066A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841314B2 (en) 2011-11-11 2014-09-23 Pfizer Inc. 2-Thiopyrimidinones

Also Published As

Publication number Publication date
US20140094472A1 (en) 2014-04-03
US9585965B2 (en) 2017-03-07
JP2016000754A (en) 2016-01-07
US20150320875A1 (en) 2015-11-12
JP5848761B2 (en) 2016-01-27
US20110319422A1 (en) 2011-12-29
AU2011270701B2 (en) 2015-05-14
CA2802733C (en) 2017-11-21
US20170196848A1 (en) 2017-07-13
EP2585066A2 (en) 2013-05-01
NZ604423A (en) 2015-01-30
JP2013541494A (en) 2013-11-14
US8592427B2 (en) 2013-11-26
ES2691671T3 (en) 2018-11-28
CA2802733A1 (en) 2011-12-29
AU2011270701A1 (en) 2013-01-10
EP2585066B1 (en) 2018-09-26
WO2011163594A2 (en) 2011-12-29
US9072788B2 (en) 2015-07-07
EP2585066A4 (en) 2014-06-11

Similar Documents

Publication Publication Date Title
WO2011163594A3 (en) Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
NZ597108A (en) Prodrugs of nh-acidic compounds
BRPI0707235B8 (en) sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation
NZ612187A (en) Multi-api loading prodrugs
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
HK1149258A1 (en) Compounds
NZ593110A (en) pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MX2011006527A (en) Dipeptide linked medicinal agents.
WO2009032034A3 (en) Stabilized picoplatin dosage form
TR201900199T4 (en) Immediate release pharmaceutical compositions containing oxycodone and naloxone.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2009011281A (en) Benzimidazoles and pharmaceutical compositions thereof.
IN2015DN04175A (en)
MA33922B1 (en) HETERAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS INHIBITORS OF ENZYME PDE10A
MX347105B (en) Pharmaceutical compositions comprising hydromorphone and naloxone.
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
EA201001747A1 (en) BENZOXASINIC DERIVATIVES, ACTING AS AN AGONIST BETA-2-ADRENOCEPTOR, FOR THE TREATMENT OF RESPIRATORY DISORDERS
MY163762A (en) Therapeutic agent for chronic renal failure
MX2012008509A (en) Therapeutic or prophylactic agent for biliary diseases.
MX2013012206A (en) Method of producing substances with supersaturated gas, transdermal delivery thereof, and uses thereof.
ATE522500T1 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
NZ731591A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
UA109793C2 (en) Arylsulphonamide derivatives for the treatment of disorders of the central nervous system
WO2012145554A3 (en) Method of producing substances with supersaturated gas,transdermal delivery device thereof, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11798995

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2802733

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013516803

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011270701

Country of ref document: AU

Date of ref document: 20110624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011798995

Country of ref document: EP